Somatomedin C (SMC; insulin-like growth factor I) is thought to mediate the effects of growth hormone (GH) mainly on skeletal growth. SMC is produced in the liver but its production by various other fetal tissues including the brain, suggests a local regulatory role rather than a general one. A substance cross-reacting with recombinant human SMC (rSMC) was localized in the central nervous system (CNS) of the normal control and Snell dwarf mice by the unlabeled antibody peroxidase-antiperoxidase technique. rSMC-immunoreactive substance (rSMC-IRS) was found in the neuronal cells of forebrain structures. These included the caudate nucleus/putamen, hippocampus, thalamus, hypothalamus, globus pallidus and amygdala. No positive cells were found in the cerebral cortex. Investigation of the dwarf brain showed rSMC-IRS distributed in identical areas of the brain, although the intensity of the staining of rSMC-IRS was found to be weaker than that of the positive cells in the normal brain. Moreover, the number of positive cells was found to be less than in the normal brain. After treatment with bovine GH for 3 days the reduced number of positive cells and weaker staining in the cerebral sections of the dwarf mice did not change. Thus, rSMC may represent another peptide which is common to both the endocrine and the nervous system, with a potential neurotransmitter/neuromodulator function in the CNS.

Keywords:
Somatomedin C, Central nervous system, Snell dwarf mouse, mmunohistochemistry
This content is only available via PDF.
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.